These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31126147)

  • 1. Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
    Diakatou M; Manes G; Bocquet B; Meunier I; Kalatzis V
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126147
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene editing prospects for treating inherited retinal diseases.
    Benati D; Patrizi C; Recchia A
    J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-Specific Knockout by CRISPR/Cas to Treat Autosomal Dominant Retinitis Pigmentosa Caused by the G56R Mutation in NR2E3.
    Diakatou M; Dubois G; Erkilic N; Sanjurjo-Soriano C; Meunier I; Kalatzis V
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress.
    Liu Y; Zong X; Cao W; Zhang W; Zhang N; Yang N
    Biomolecules; 2024 Jul; 14(8):. PubMed ID: 39199291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa.
    Bakondi B; Lv W; Lu B; Jones MK; Tsai Y; Kim KJ; Levy R; Akhtar AA; Breunig JJ; Svendsen CN; Wang S
    Mol Ther; 2016 Mar; 24(3):556-63. PubMed ID: 26666451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal dominant retinitis pigmentosa with toxic gain of function: Mechanisms and therapeutics.
    Narasimhan I; Murali A; Subramanian K; Ramalingam S; Parameswaran S
    Eur J Ophthalmol; 2021 Mar; 31(2):304-320. PubMed ID: 32962414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.
    Meng D; Ragi SD; Tsang SH
    Mol Ther; 2020 Oct; 28(10):2139-2149. PubMed ID: 32882181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model.
    Patrizi C; Llado M; Benati D; Iodice C; Marrocco E; Guarascio R; Surace EM; Cheetham ME; Auricchio A; Recchia A
    Am J Hum Genet; 2021 Feb; 108(2):295-308. PubMed ID: 33508235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes.
    Daich Varela M; Georgiadis A; Michaelides M
    Br J Ophthalmol; 2023 Sep; 107(9):1223-1230. PubMed ID: 36038193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa.
    Hu S; Du J; Chen N; Jia R; Zhang J; Liu X; Yang L
    Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):31. PubMed ID: 32330228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele-specific gene-editing approach for vision loss restoration in
    Liu X; Qiao J; Jia R; Zhang F; Meng X; Li Y; Yang L
    Elife; 2023 Jun; 12():. PubMed ID: 37272616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.
    Hansen S; McClements ME; Corydon TJ; MacLaren RE
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice.
    Murro V; Banfi S; Testa F; Iarossi G; Falsini B; Sodi A; Signorini S; Iolascon A; Russo R; Mucciolo DP; Caputo R; Bacci GM; Bargiacchi S; Turco S; Fortini S; Simonelli F
    Orphanet J Rare Dis; 2023 Jul; 18(1):223. PubMed ID: 37525225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome Surgery and Gene Therapy in Retinal Disorders.
    Chan L; Mahajan VB; Tsang SH
    Yale J Biol Med; 2017 Dec; 90(4):523-532. PubMed ID: 29259518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eye on genome editing.
    Du SW; Palczewski K
    J Exp Med; 2023 May; 220(5):. PubMed ID: 36930175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa.
    Berger A; Lorain S; Joséphine C; Desrosiers M; Peccate C; Voit T; Garcia L; Sahel JA; Bemelmans AP
    Mol Ther; 2015 May; 23(5):918-930. PubMed ID: 25619725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.
    Pulman J; Sahel JA; Dalkara D
    CRISPR J; 2022 Jun; 5(3):377-388. PubMed ID: 35506982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Course of Ocular Function in PRPF31 Retinitis Pigmentosa.
    Hafler BP; Comander J; Weigel DiFranco C; Place EM; Pierce EA
    Semin Ophthalmol; 2016; 31(1-2):49-52. PubMed ID: 26959129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa.
    Wu WH; Tsai YT; Huang IW; Cheng CH; Hsu CW; Cui X; Ryu J; Quinn PMJ; Caruso SM; Lin CS; Tsang SH
    Mol Ther; 2022 Apr; 30(4):1407-1420. PubMed ID: 35150888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zebrafish as a Model to Evaluate a CRISPR/Cas9-Based Exon Excision Approach as a Future Treatment Option for
    Schellens R; de Vrieze E; Graave P; Broekman S; Nagel-Wolfrum K; Peters T; Kremer H; Collin RWJ; van Wijk E
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.